Sign in

    Shrikant Akolkar

    Research Analyst at Nuvama Wealth

    Shrikant Akolkar is a Research Analyst at Nuvama Wealth Management Ltd., specializing in coverage of the healthcare and specialty chemicals sectors with a focus on Indian pharmaceutical companies such as Aarti Pharmalabs and Dr Reddy's Laboratories. He is actively involved in industry conferences and earnings calls, providing insights that have contributed to informed client investment decisions and company market analysis. Akolkar began his career at Angel One Ltd. as Assistant Vice President before joining Nuvama Wealth Management, further establishing his expertise in sectoral research. His credentials are rooted in a solid track record in equity research, and he is recognized for his analytical contributions within the institutional investor community.

    Shrikant Akolkar's questions to DR REDDYS LABORATORIES (RDY) leadership

    Shrikant Akolkar's questions to DR REDDYS LABORATORIES (RDY) leadership • Q4 2025

    Question

    Shrikant Akolkar inquired about the competitive landscape for generic semaglutide in Canada, noting four filers, and asked about Dr. Reddy's specific approval timeline.

    Answer

    CEO Erez Israeli stated that while he cannot predict which competitors will launch, Dr. Reddy's plans to be ready to launch on the date the market opens. He expects to receive approval sometime near the end of the current calendar year (2025).

    Ask Fintool Equity Research AI